Prevention of VTE in multiple myeloma patients

Thrombosis Research

Volumn 120, Issue SUPPL. 2, 2007, Pages

  Zamagni, Elena ^a   Valdrè, Lelia ^a   Palareti, Gualtiero ^a   Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Multiple myeloma; Thalidomide; Thromboprophylaxis; VTE

Indexed keywords

ACETYLSALICYLIC ACID; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LENALIDOMIDE; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; PREDNISONE; THALIDOMIDE; WARFARIN;

ANTICOAGULATION; ARTICLE; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL TRIAL; GENETIC POLYMORPHISM; HUMAN; MULTIPLE MYELOMA; MUTATION; PRIORITY JOURNAL; RISK ASSESSMENT; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; CLINICAL TRIALS AS TOPIC; HUMANS; MULTIPLE MYELOMA; VENOUS THROMBOEMBOLISM;

EID: 36048979309     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(07)70142-1     Document Type: Article

References (9)

1. Srkalovic G., Cameron M., Rybicki L., et al. Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101 (2004) 558-566
2. Rodeghiero F., and Elice F. Thalidomide and thrombosis. Pathophysiol Haemost Thromb 33 1 (2003) 15-18
3. Zangari M., Anaissie E., Barlogie B., et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98 (2001) 1614-1615
4. Rajkumar V. Thalidomide therapy and deep venous thrombosis in multiple myeloma. Mayo Clinic Proc 80 12 (2005) 1549-1551
5. Hussein M. Thromboembolism risk reduction in multiple myeloma patients treated with immunomodulatory drug combinations. Thromb Haemost 95 (2006) 924-930
6. Zangari M., Barlogie B., Anaissie E., et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy. Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 126 (2004) 715-721
7. Baz R., Marchant K., Yiannaki E., et al. Aspirin decreases the thrombotic complications (DVT) of liposomal doxorubicin, vincristine, dexamethasone and thalidomide (DVd-T) treatment for multiple myeloma (MM). Blood 104 (2004) 2397
8. Cavo M., Zamagni E., Tosi P., et al. First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 89 (2004) 826-831
9. Elice F., Fink L., Tricot G., et al. Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism. Br J Haematol 134 (2006) 399-405